ClinConnect ClinConnect Logo
Search / Trial NCT02476695

FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis

Launched by WUXI HISKY MEDICAL TECHNOLOGY CO LTD · Jun 16, 2015

Trial Information

Current as of September 16, 2025

Completed

Keywords

Chb

ClinConnect Summary

The liver diseases frequently occur in China. For various reasons, the chronic liver diseases are not controlled in time, and then develop gradually into liver fibrosis and cirrhosis. Without effective treatment, the advanced liver cirrhosis seriously influences the quality of patients' life, and places an intolerable burden on family and society. At present, the scholars generally thought that the liver fibrosis at early stages is reversible. Therefore, if the liver fibrosis in patients with chronic liver diseases can be accurately evaluated at early stages and be treated in time, so we ca...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects with age 18-65 years, both gender
  • Subjects with history of HBV or HBsAg positive \> 6 months up to enrollment
  • Subjects with qualified liver biopsy specimens within three months (before or after) of Fibrotouch examination for pathological staging
  • Subjects without chemical therapy history of powerful medicine to lower enzyme in the two weeks before blood biochemistry tests (e.g. dimethyl diphenyl bicarboxylate and bicyclol)
  • Subjects must agree and sign the informed consent form
  • Exclusion Criteria:
  • Subjects who are unable or unwilling to sign informed consent form
  • Subjects who have merger of hepatitis C, alcohol and non-alcoholic fatty liver diseases, autoimmune liver diseases, inherited metabolic liver diseases, biliary systemic diseases or liver and gall parasitic diseases
  • Subjects who have other serious chronic disorders or history of malignancy
  • Subjects with ALT ≥5 ULN in the past 1 month
  • Subjects with WBC\<3.5×10\^9/L, PLT\<60×10\^9/L, PTA\<60%
  • Subjects with DBIL≥1.5 ULN
  • Subjects with decompensated cirrhosis (especially the people with ascites)
  • Pregnant or lactating women, or women who has a pregnant plan and don't want to birth control in the study period
  • Subjects who have wound on the right upper abdomen recently
  • Subjects who have various space-occupying tumor or cyst in right liver
  • Subjects who have none or limited legal capacity

About Wuxi Hisky Medical Technology Co Ltd

WuXi Hisky Medical Technology Co., Ltd. is a leading clinical trial sponsor dedicated to advancing innovative healthcare solutions through cutting-edge medical technologies. With a strong emphasis on research and development, WuXi Hisky specializes in the design and execution of clinical trials that adhere to the highest regulatory standards. The company leverages its extensive expertise and state-of-the-art facilities to support pharmaceutical and biotechnology partners in bringing new therapies to market efficiently and effectively. Committed to enhancing patient outcomes, WuXi Hisky fosters collaborations that drive scientific progress and improve the quality of life globally.

Locations

Chengdu, China

Tianjin, China

Zhengzhou, China

Shanghai, China

Beijing, China

Beijing, China

Beijing, China

Changchun, China

Chongqing, China

Guangzhou, China

Nanjing, China

Shanghai, China

Shijiazhuang, China

Urumqi, China

Xi'an, China

Patients applied

0 patients applied

Trial Officials

Jidong JIA, MD

Study Chair

Beijing Friendship Hospital

Jianbiao CAO, MD

Principal Investigator

The Military General Hospital of Beijing, PLA

Qing MAO, MD

Principal Investigator

The First Affiliated Hospital, Third Military University

Ying HAN, MD

Principal Investigator

The First Affiliated Hospital of the Fourth Military Medical University

Junqi NIU, MD

Principal Investigator

The First Hospital of Jilin University

Yuemin NAN, MD

Principal Investigator

Hebei Medical University Third Hospital

JIA SHANG, MD

Principal Investigator

Henan Provincial People's Hospital

Jun LI, MD

Principal Investigator

Jiangsu Provincial People's Hospital

Qing XIE, MD

Principal Investigator

Ruijin Hospital

Hong TANG, MD

Principal Investigator

West China Hospital

Tao HAN, MD

Principal Investigator

Tianjin Third Central Hospital

Qingchun FU, MD

Principal Investigator

No.85 Hospital, Changning, Shanghai, China

Zhiliang GAO, MD

Principal Investigator

Third Affiliated Hospital, Sun Yat-Sen University

Xiaozhong WANG, MD

Principal Investigator

Hospital of Chinese Medicine of the Xinjiang Uygur Autonomous Region

Anlin MA, MD

Principal Investigator

The China-Japan Friendship Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials